DNTH: Multiple clinical milestones and strong financials position the pipeline for major neuromuscular market impact
Significant pipeline progress was highlighted, including positive clinical data for claseprubart in MG and CIDP, with MMN phase II results and several key updates expected by year-end. The company is well-positioned in competitive neuromuscular markets and has a strong cash runway to support ongoin…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.